HDAC Inhibition Increases HLA Class I Expression in Uveal Melanoma
Abstract
:Simple Summary
Abstract
1. Introduction
2. Results
2.1. HDAC and EZH2 Expression in UM, Association with High Risk
2.2. Association between HDAC and EZH2 Expression and HLA Class I in UM
2.3. In Vitro Analysis of Effect of HDAC and EZH2 Inhibition on UM Cell Lines
2.3.1. Morphological Analysis of UM Cell Lines after 48 h Treatment with Quisinostat and Tazemetostat
2.3.2. Quisinostat and Cell Growth
2.3.3. Effect of Quisinostat and Tazemetostat on HLA Class I Cell Surface Expression
2.3.4. Effect of Quisinostat and Tazemetostat on HLA Class I mRNA Expression by qPCR
3. Discussion
4. Materials and Methods
4.1. Study Population
4.2. Chromosome Analysis
4.3. Immunohistochemistry
4.4. Tumour Gene Expression
4.5. Reagents
4.6. Cell Lines and Cell Culture
4.7. Cell Proliferation Study
4.8. Flow Cytometry
4.9. RNA Isolation and Quantitative Real-Time Polymerase Chain Reaction (qPCR)
4.10. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Conflicts of Interest
References
- Virgili, G.; Gatta, G.; Ciccolallo, L.; Capocaccia, R.; Biggeri, A.; Crocetti, E.; Lutz, J.-M.; Paci, E. Incidence of Uveal Melanoma in Europe. Ophthalmology 2007, 114, 2309–2315. [Google Scholar] [CrossRef]
- Singh, A.D.; Topham, A. Incidence of uveal melanoma in the United States: 1973–1997. Ophthalmology 2003, 110, 956–961. [Google Scholar] [CrossRef]
- Kujala, E.; Mäkitie, T.; Kivelä, T. Very Long-Term Prognosis of Patients with Malignant Uveal Melanoma. Investig. Opthalmol. Vis. Sci. 2003, 44, 4651–4659. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jager, M.J.; Shields, C.L.; Cebulla, C.M.; Abdel-Rahman, M.H.; Grossniklaus, H.E.; Stern, M.H.; Carvajal, R.D.; Belfort, R.N.; Jia, R.; Shields, J.A.; et al. Uveal melanoma. Nat. Rev. Dis. Primers 2020, 6, 1–25. [Google Scholar] [CrossRef] [PubMed]
- Jager, M.J.; Hurks, H.M.H.; Levitskaya, J.; Kiessling, R. HLA expression in uveal melanoma: There is no rule without some exception. Hum. Immunol. 2002, 63, 444–451. [Google Scholar] [CrossRef]
- Bronkhorst, I.H.; Vu, T.H.K.; Jordanova, E.S.; Luyten, G.P.M.; Burg, S.H.V.D.; Jager, M.J. Different Subsets of Tumor-Infiltrating Lymphocytes Correlate with Macrophage Influx and Monosomy 3 in Uveal Melanoma. Investig. Opthalmol. Vis. Sci. 2012, 53, 5370–5378. [Google Scholar] [CrossRef] [Green Version]
- Robertson, A.G.; Shih, J.; Yau, C.; Gibb, E.A.; Oba, J.; Mungall, K.L.; Hess, J.M.; Uzunangelov, V.; Walter, V.; Danilova, L.; et al. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell 2017, 32, 204–220.e15. [Google Scholar] [CrossRef]
- Blom, D.J.; Luyten, G.P.; Mooy, C.; Kerkvliet, S.; Zwinderman, A.H.; Jager, M.J. Human leukocyte antigen class I expression. Marker of poor prognosis in uveal melanoma. Investig. Ophthalmol. Vis. Sci. 1997, 38, 1865–1872. [Google Scholar]
- Dithmar, S.; Crowder, J.; Jager, M.J.; Vigniswaran, N.; Grossniklaus, H.E. HLA-I-Antigenexpression korreliert mit dem histologischen Zelltyp uvealer Melanome. Der Ophthalmol. 2002, 99, 625–628. [Google Scholar] [CrossRef]
- Ericsson, C.; Seregard, S.; Bartolazzi, A.; Levitskaya, E.; Ferrone, S.; Kiessling, R.; Larsson, O. Association of HLA class I and class II antigen expression and mortality in uveal melanoma. Investig. Ophthalmol. Vis. Sci. 2001, 42, 2153–2156. [Google Scholar]
- Ma, D.; Niederkorn, J.Y. Transforming growth factor-beta down-regulates major histocompatibility complex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis. Immunology 1995, 86, 263–269. [Google Scholar] [PubMed]
- Ma, D.; Luyten, G.P.; Luider, T.M.; Niederkorn, J.Y. Relationship between natural killer cell susceptibility and metastasis of human uveal melanoma cells in a murine model. Investig. Ophthalmol. Vis. Sci. 1995, 36, 435–441. [Google Scholar]
- Niederkorn, J.Y. Immune escape mechanisms of intraocular tumors. Prog. Retin. Eye Res. 2009, 28, 329–347. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Garcia-Lora, A.; Algarra, I.; Garrido, F. MHC class I antigens, immune surveillance, and tumor immune escape. J. Cell. Physiol. 2003, 195, 346–355. [Google Scholar] [CrossRef] [PubMed]
- Campoli, M.; Ferrone, S. HLA antigen changes in malignant cells: Epigenetic mechanisms and biologic significance. Oncogene 2008, 27, 5869–5885. [Google Scholar] [CrossRef] [Green Version]
- Van Essen, T.; Van Pelt, S.I.; Bronkhorst, I.H.G.; Versluis, M.; Némati, F.; Laurent, C.; Luyten, G.P.M.; Van Hall, T.; Elsen, P.J.V.D.; Van Der Velden, P.A.; et al. Upregulation of HLA Expression in Primary Uveal Melanoma by Infiltrating Leukocytes. PLoS ONE 2016, 11, e0164292. [Google Scholar] [CrossRef]
- Souri, Z.; Wierenga, A.P.A.; Mulder, A.; Jochemsen, A.G.; Jager, M.J. HLA Expression in Uveal Melanoma: An Indicator of Malignancy and a Modifiable Immunological Target. Cancers 2019, 11, 1132. [Google Scholar] [CrossRef] [Green Version]
- Holling, T.M.; Bergevoet, M.W.T.; Wilson, L.; Van Eggermond, M.C.J.A.; Schooten, E.; Steenbergen, R.D.; Snijders, P.J.F.; Jager, M.J.; Elsen, P.J.V.D. A Role for EZH2 in Silencing of IFN-γ Inducible MHC2TA Transcription in Uveal Melanoma. J. Immunol. 2007, 179, 5317–5325. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Magner, W.J.; Kazim, A.L.; Stewart, C.; Romano, M.A.; Catalano, G.; Grande, C.; Keiser, N.; Santaniello, F.; Tomasi, T.B. Activation of MHC Class I, II, and CD40 Gene Expression by Histone Deacetylase Inhibitors. J. Immunol. 2000, 165, 7017–7024. [Google Scholar] [CrossRef]
- Mora-García, M.D.L.; Duenas-Gonzalez, A.; Hernández-Montes, J.; De La Cruz-Hernández, E.; Perez-Cardenas, E.; Weiss-Steider, B.; Santiago-Osorio, E.; Ortiz-Navarrete, V.; Rosales, V.H.; Cantú, D.; et al. Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid. J. Transl. Med. 2006, 4, 55. [Google Scholar] [CrossRef] [Green Version]
- Kitamura, H.; Torigoe, T.; Asanuma, H.; Honma, I.; Sato, N.; Tsukamoto, T. Down-Regulation of HLA Class I Antigens in Prostate Cancer Tissues and Up-Regulation by Histone Deacetylase Inhibition. J. Urol. 2007, 178, 692–696. [Google Scholar] [CrossRef] [PubMed]
- Khan, A.N.H.; Gregorie, C.J.; Tomasi, T.B. Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol. Immunother. 2008, 57, 647–654. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Herlihy, N.; Dogrusöz, M.; Van Essen, T.H.; Harbour, J.W.; Van Der Velden, P.A.; Van Eggermond, M.C.J.A.; Haasnoot, G.W.; Elsen, P.J.V.D.; Jager, M.J. Skewed Expression of the Genes Encoding Epigenetic Modifiers in High-Risk Uveal Melanoma. Investig. Opthalmol. Vis. Sci. 2015, 56, 1447–1458. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, Y.; Jia, R.; Ge, S. Role of Epigenetics in Uveal Melanoma. Int. J. Biol. Sci. 2017, 13, 426–433. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Landreville, S.; Agapova, O.A.; Matatall, K.A.; Kneass, Z.T.; Onken, M.D.; Lee, R.S.; Bowcock, A.M.; Harbour, J.W. Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma. Clin. Cancer Res. 2012, 18, 408–416. [Google Scholar] [CrossRef] [Green Version]
- Triozzi, P.L.; Singh, A.D. Adjuvant Therapy of Uveal Melanoma: Current Status. Ocul. Oncol. Pathol. 2015, 1, 54–62. [Google Scholar] [CrossRef] [Green Version]
- Jespersen, H.; Bagge, R.O.; Ullenhag, G.; Carneiro, A.; Helgadottir, H.; Ljuslinder, I.; Levin, M.; All-Eriksson, C.; Andersson, B.; Stierner, U.; et al. Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): Protocol for a multicenter phase II open label study. BMC Cancer 2019, 19, 415–421. [Google Scholar] [CrossRef] [Green Version]
- Cheng, Y.; Li, Y.; Huang, X.; Wei, W.; Qu, Y. Expression of EZH2 in uveal melanomas patients and associations with prognosis. Oncotarget 2017, 8, 76423–76431. [Google Scholar] [CrossRef] [Green Version]
- Heijkants, R.; Willekens, K.; Schoonderwoerd, M.; Teunisse, A.; Nieveen, M.; Radaelli, E.; Hawinkels, L.; Marine, J.-C.; Jochemsen, A.G. Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma. Oncotarget 2017, 9, 6174–6187. [Google Scholar] [CrossRef] [Green Version]
- Moschos, M.M.; Dettoraki, M.; Androudi, S.; Kalogeropoulos, D.; Lavaris, A.; Mantas, D.; Damaskos, C.; Garmpi, A.; Tsatsos, M. The Role of Histone Deacetylase Inhibitors in Uveal Melanoma: Current Evidence. Anticancer. Res. 2018, 38, 3817–3824. [Google Scholar] [CrossRef]
- Lu, J.; Sun, H.; Wang, X.; Liu, C.; Xu, X.; Li, F.; Huang, B. Interleukin-12 p40 promoter activity is regulated by the reversible acetylation mediated by HDAC1 and p300. Cytokine 2005, 31, 46–51. [Google Scholar] [CrossRef] [PubMed]
- Shakespear, M.R.; Halili, M.A.; Irvine, K.M.; Fairlie, D.P.; Sweet, M.J. Histone deacetylases as regulators of inflammation and immunity. Trends Immunol. 2011, 32, 335–343. [Google Scholar] [CrossRef] [PubMed]
- Zhang, H.; Li, X.; Zhang, Q.; Yang, F.; Chu, X.; Zhang, D.; Wang, L.; Gong, Z. Role of histone deacetylase expression levels and activity in the inflammatory responses of patients with chronic hepatitis B. Mol. Med. Rep. 2017, 15, 2744–2752. [Google Scholar] [CrossRef] [PubMed]
- Angiolilli, C.; Kabala, P.A.; Grabiec, A.M.; Van Baarsen, I.M.; Ferguson, B.S.; García, S.; Fernandez, B.M.; McKinsey, T.A.; Tak, P.P.; Fossati, G.; et al. Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes. Ann. Rheum. Dis. 2016, 76, 277–285. [Google Scholar] [CrossRef]
- Nusinzon, I.; Horvath, C.M. Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc. Natl. Acad. Sci. USA 2003, 100, 14742–14747. [Google Scholar] [CrossRef] [Green Version]
- Klampfer, L.; Augenlicht, L.; Huang, J.; Swaby, L.-A. Requirement of Histone Deacetylase Activity for Signaling by STAT1. J. Biol. Chem. 2004, 279, 30358–30368. [Google Scholar] [CrossRef] [Green Version]
- Van Der Ent, W.; Burrello, C.; Teunisse, A.F.A.S.; Ksander, B.R.; Van Der Velden, P.A.; Jager, M.J.; Jochemsen, A.G.; Snaar-Jagalska, B.E. Modeling of Human Uveal Melanoma in Zebrafish Xenograft Embryos. Investig. Opthalmol. Vis. Sci. 2014, 55, 6612–6622. [Google Scholar] [CrossRef]
- Venugopal, B.; Baird, R.D.; Kristeleit, R.; Plummer, R.; Cowan, R.A.; Stewart, A.; Fourneau, N.; Hellemans, P.; Elsayed, Y.; McClue, S.; et al. A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors. Clin. Cancer Res. 2013, 19, 4262–4272. [Google Scholar] [CrossRef] [Green Version]
- Bao, L.; Diao, H.; Dong, N.; Su, X.; Wang, B.; Mo, Q.; Yu, H.; Wang, X.; Chen, C. Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation. Cell Biol. Toxicol. 2016, 32, 469–482. [Google Scholar] [CrossRef] [Green Version]
- He, B.; Dai, L.; Zhang, X.; Chen, D.; Wu, J.; Feng, X.; Zhang, Y.; Xie, H.; Zhou, L.; Wu, J.; et al. The HDAC Inhibitor Quisinostat (JNJ-26481585) Supresses Hepatocellular Carcinoma alone and Synergistically in Combination with Sorafenib by G0/G1 phase arrest and Apoptosis induction. Int. J. Biol. Sci. 2018, 14, 1845–1858. [Google Scholar] [CrossRef]
- Zhang, H.; Zhu, D.; Zhang, Z.; Kaluz, S.; Yu, B.; Devi, N.S.; Olson, J.J.; Van Meir, E.G. Correction: EZH2 targeting reduces medulloblastoma growth through epigenetic reactivation of the BAI1/p53 tumor suppressor pathway. Oncogene 2020, 39, 1165. [Google Scholar] [CrossRef] [PubMed]
- Italiano, A.; Soria, J.C.; Toulmonde, M.; Michot, J.M.; Lucchesi, C.; Varga, A.; Coindre, J.M.; Blakemore, S.J.; Clawson, A.; Suttle, B.; et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: A first-in-human, open-label, phase 1 study. Lancet Oncol. 2018, 19, 649–659. [Google Scholar] [CrossRef]
- Ritter, C.; Fan, K.; Paschen, A.; Hardrup, S.R.; Ferrone, S.; Nghiem, P.; Ugurel, S.; Schrama, D.; Becker, J.C. Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma. Sci. Rep. 2017, 7, 2290–2300. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Leslie, P.L.; Chao, Y.L.; Tsai, Y.-H.; Ghosh, S.K.; Porrello, A.; Van Swearingen, A.E.D.; Harrison, E.B.; Cooley, B.C.; Parker, J.S.; Carey, L.A.; et al. Histone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes. Nat. Commun. 2019, 10, 1–12. [Google Scholar] [CrossRef] [Green Version]
- Versluis, M.; De Lange, M.J.; Van Pelt, S.I.; Ruivenkamp, C.A.L.; Kroes, W.G.M.; Cao, J.; Jager, M.J.; Luyten, G.P.M.; Van Der Velden, P.A. Digital PCR Validates 8q Dosage as Prognostic Tool in Uveal Melanoma. PLoS ONE 2015, 10, e0116371. [Google Scholar] [CrossRef] [Green Version]
- Koopmans, A.E.; Verdijk, R.M.; Brouwer, R.W.; van den Bosch, T.P.; van den Berg, M.M.; Vaarwater, J.; Kockx, C.E.M.; Paridaens, D.; Naus, N.C.; Nellist, M.; et al. Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma. Mod. Pathol. 2014, 27, 1321–1330. [Google Scholar] [CrossRef] [Green Version]
- Van Essen, T.H.; Van Pelt, S.I.; Versluis, M.; Bronkhorst, I.H.G.; Van Duinen, S.G.; Marinkovic, M.; Kroes, W.G.M.; Ruivenkamp, C.A.L.; Shukla, S.; De Klein, A.; et al. Prognostic parameters in uveal melanoma and their association with BAP1 expression. Br. J. Ophthalmol. 2014, 98, 1738–1743. [Google Scholar] [CrossRef] [Green Version]
- Luyten, G.P.M.; Naus, N.C.; Mooy, C.M.; Hagemeijer, A.; Kan-Mitchell, J.; Van Drunen, E.; Vuzevski, V.; De Jong, P.T.V.M.; Luider, T.M. Establishment and characterization of primary and metastatic uveal melanoma cell lines. Int. J. Cancer 1996, 66, 380–387. [Google Scholar] [CrossRef]
- Chen, P.W.; Murray, T.G.; Uno, T.; Salgaller, M.L.; Reddy, R.; Ksander, B.R. Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease. Clin. Exp. Metastasis 1997, 15, 509–518. [Google Scholar] [CrossRef]
- Amirouchene-Angelozzi, N.; Nemati, F.; Gentien, D.; Nicolas, A.; Dumont, A.; Carita, G.; Camonis, J.; Desjardins, L.; Cassoux, N.; Piperno-Neumann, S.; et al. Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target. Mol. Oncol. 2014, 8, 1508–1520. [Google Scholar] [CrossRef]
- Bronkhorst, I.H.G.; Jehs, T.M.L.; Dijkgraaf, E.M.; Luyten, G.P.M.; Van Der Velden, P.A.; Van Der Burg, S.H.; Jager, M.J. Effect of Hypoxic Stress on Migration and Characteristics of Monocytes in Uveal Melanoma. JAMA Ophthalmol. 2014, 132, 614–621. [Google Scholar] [CrossRef] [PubMed] [Green Version]
HLA-A Probe 1 | HLA-A Probe 2 | HLA-A Probe 3 | HLA-B | |||||
---|---|---|---|---|---|---|---|---|
R | p | R | p | R | p | R | p | |
HDAC1 | 0.367 | 0.003 | 0.392 | 0.001 | 0.380 | 0.002 | 0.370 | 0.003 |
HDAC2 | −0.144 | 0.26 | −0.167 | 0.19 | −0.108 | 0.40 | −0.162 | 0.20 |
HDAC3 | 0.262 | 0.04 | 0.241 | 0.05 | 0.293 | 0.02 | 0.318 | 0.01 |
HDAC4 | 0.143 | 0.26 | 0.371 | 0.003 | 0.354 | 0.004 | 0.305 | 0.01 |
HDAC5 probe 1 | 0.029 | 0.82 | 0.090 | 0.48 | 0.018 | 0.88 | −0.045 | 0.72 |
HDAC5 probe 2 | 0.091 | 0.47 | 0.231 | 0.07 | 0.096 | 0.45 | 0.151 | 0.23 |
HDAC6 | −0.179 | 0.16 | −0.136 | 0.28 | −0.284 | 0.02 | −0.196 | 0.12 |
HDAC7 probe 1 | −0.020 | 0.87 | 0.010 | 0.94 | −0.014 | 0.91 | 0.108 | 0.39 |
HDAC7 probe 2 | 0.225 | 0.07 | 0.382 | 0.002 | 0.263 | 0.04 | 0.352 | 0.004 |
HDAC8 | 0.456 | <0.001 | 0.588 | <0.001 | 0.539 | <0.001 | 0.550 | <0.001 |
HDAC9 | −0.066 | 0.60 | −0.091 | 0.48 | −0.209 | 0.01 | −0.190 | 0.13 |
HDAC11 | −0.541 | <0.001 | −0.548 | <0.001 | −0.515 | <0.001 | −0.607 | <0.001 |
EZH2 | 0.211 | 0.09 | 0.214 | 0.09 | 0.226 | 0.07 | 0.146 | 0.25 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Souri, Z.; Jochemsen, A.G.; Versluis, M.; Wierenga, A.P.A.; Nemati, F.; van der Velden, P.A.; Kroes, W.G.M.; Verdijk, R.M.; Luyten, G.P.M.; Jager, M.J. HDAC Inhibition Increases HLA Class I Expression in Uveal Melanoma. Cancers 2020, 12, 3690. https://doi.org/10.3390/cancers12123690
Souri Z, Jochemsen AG, Versluis M, Wierenga APA, Nemati F, van der Velden PA, Kroes WGM, Verdijk RM, Luyten GPM, Jager MJ. HDAC Inhibition Increases HLA Class I Expression in Uveal Melanoma. Cancers. 2020; 12(12):3690. https://doi.org/10.3390/cancers12123690
Chicago/Turabian StyleSouri, Zahra, Aart G. Jochemsen, Mieke Versluis, Annemijn P.A. Wierenga, Fariba Nemati, Pieter A. van der Velden, Wilma G.M. Kroes, Robert M. Verdijk, Gregorius P.M. Luyten, and Martine J. Jager. 2020. "HDAC Inhibition Increases HLA Class I Expression in Uveal Melanoma" Cancers 12, no. 12: 3690. https://doi.org/10.3390/cancers12123690